Restricted accessResearch articleFirst published online 2026
Salivary metabolomics for early detection of vascular contributions to cognitive impairment and dementia: Exploring microbiome dysbiosis and sex differences
Vascular factors contribute to dementia in approximately 20 million individuals, notably in vascular contributions to cognitive impairment and dementia (VCI). However, the lack of specific molecular biomarkers to differentiate VCI from normal aging and Alzheimer's disease (AD) impedes early diagnosis and treatment.
Objective
To date the use of saliva for VCI diagnosis has not been previously reported. In this small proof-of-concept study, we aim to explore the feasibility of screening novel salivary diagnostic biomarkers for VCI.
Methods
Using both proton nuclear magnetic resonance (1H NMR) spectroscopy and liquid chromatography coupled with mass spectrometry (LC-MS) we biochemically profiled saliva samples collected from individuals with VCI (n = 26) and compared them with cognitively healthy controls (n = 37).
Results
Of the 167 salivary metabolites 56 of them are found to be at significantly different concentrations in the saliva of individuals with VCI as compared to controls. Subsequently, we developed predictive models capable of distinguishing VCI from controls with 0.92 accuracy. Moreover, sex-stratified analysis revealed the perturbation of different metabolic pathways in the saliva of individuals with VCI.
Conclusions
This study underscores the promising role of salivary metabolomics as a non-invasive tool for the early detection of VCI. Our findings suggest that oral microbiome dysbiosis may contribute to VCI pathogenesis, offering novel mechanistic insights. Given the accessibility of saliva, further validation of these robust salivary biomarkers could facilitate scalable, cost-effective screening for VCI, aiding in timely intervention strategies.
RundekTToleaMArikoT, et al.Vascular cognitive impairment (VCI). Neurotherapeutics2022; 19: 68–88.
3.
HeYHeTLiH, et al.Deciphering mitochondrial dysfunction: pathophysiological mechanisms in vascular cognitive impairment. Biomed Pharmacother2024; 174: 116428.
4.
BiesbroekJMBiesselsGJ. Diagnosing vascular cognitive impairment: current challenges and future perspectives. Int J Stroke2023; 18: 36–43.
5.
MokVCTCaiYMarkusHS. Vascular cognitive impairment and dementia: mechanisms, treatment, and future directions. Int J Stroke2024; 19: 838–856.
6.
LeventhalMJZanellaCAKangB, et al.An integrative systems-biology approach defines mechanisms of Alzheimer's disease neurodegeneration. Nat Commun2025; 16: 4441.
7.
AkyolSAshrafiNYilmazA, et al.Metabolomics: an emerging “omics” platform for systems biology and its implications for huntington disease research. Metabolites2023; 13: 1203.
8.
RyanDGYangMPragHA, et al.Disruption of the TCA cycle reveals an ATF4-dependent integration of redox and amino acid metabolism. Elife2021; 10: e72593.
9.
YilmazAGeddesTHanB, et al.Diagnostic biomarkers of Alzheimer's disease as identified in saliva using 1H NMR-based metabolomics. J Alzheimers Dis2017; 58: 355–359.
10.
HyvärinenESoljeEVepsäläinenJ, et al.Salivary metabolomics in the diagnosis and monitoring of neurodegenerative dementia. Metabolites2023; 13: 233.
11.
GorelickPBScuteriABlackSE, et al.Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American stroke association. Stroke2011; 42: 2672–2713.
12.
RavanbakhshSLiuPBjordahlTC, et al.Accurate, fully-automated NMR spectral profiling for metabolomics. PloS One2015; 10: e0124219.
13.
KimKYKimBJYiGS. Reuse of imputed data in microarray analysis increases imputation efficiency. BMC Bioinformatics2004; 5: 160.
14.
RitchieMEPhipsonBWuD, et al.Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res2015; 43: e47.
15.
WuTHuEXuS, et al.Clusterprofiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb)2021; 2: 100141.
16.
KuhnM. Building predictive models in R using the caret package. J Stat Softw2008; 28: 1–26.
17.
FriedmanJHHastieTTibshiraniR. Regularization paths for generalized linear models via coordinate descent. J Stat Softw2010; 33: 1–22.
18.
HoTK. Random decision forests.Proceedings of 3rd international conference on document analysis and recognition 14-16 Aug 1995. Piscataway, NJ: IEEE, 1995, pp.278–282.
19.
RosenbergGA. Vascular cognitive impairment: biomarkers in diagnosis and molecular targets in therapy. J Cereb Blood Flow Metab2016; 36: 4–5.
20.
AroKWeiFWongDT, et al.Saliva liquid biopsy for point-of-care applications. Front Public Health2017; 5: 77.
21.
KashyapBKullaaA. Salivary metabolites produced by oral microbes in oral diseases and oral squamous cell carcinoma: a review. Metabolites2024; 14: 277.
22.
MaitreYMahalliRMicheneauP, et al.Evidence and therapeutic perspectives in the relationship between the oral microbiome and Alzheimer's disease: a systematic review. Int J Environ Res Public Health2021; 18: 11157.
23.
WanJFanH. Oral microbiome and Alzheimer's disease. Microorganisms2023; 11: 2550.
24.
MaoSHuangCPLanH, et al.Association of periodontitis and oral microbiomes with Alzheimer's disease: a narrative systematic review. J Dent Sci2022; 17: 1762–1779.
RiviereGRRiviereKHSmithKS. Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer's disease. Oral Microbiol Immunol2002; 17: 113–118.
27.
HorlianaACChambroneLFozAM, et al.Dissemination of periodontal pathogens in the bloodstream after periodontal procedures: a systematic review. PloS One2014; 9: e98271.
28.
BergRD. Bacterial translocation from the gastrointestinal tract. Adv Exp Med Biol1999; 473: 11–30.
29.
RhodesAEvansLEAlhazzaniW, et al.Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med2017; 43: 304–377.
30.
LogsdonAFEricksonMARheaEM, et al.Gut reactions: how the blood-brain barrier connects the microbiome and the brain. Exp Biol Med (Maywood)2018; 243: 159–165.
31.
SweeneyMDSagareAPZlokovicBV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol2018; 14: 133–150.
32.
CalsolaroVEdisonP. Neuroinflammation in Alzheimer's disease: current evidence and future directions. Alzheimers Dement2016; 12: 719–732.
33.
ReddyPHTripathiRTroungQ, et al.Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta2012; 1822: 639–649.
34.
ZhaoWWangJVargheseM, et al.Impaired mitochondrial energy metabolism as a novel risk factor for selective onset and progression of dementia in oldest-old subjects. Neuropsychiatr Dis Treat2015; 11: 565–574.
35.
PagliaGStoccheroMCacciatoreS, et al.Unbiased metabolomic investigation of Alzheimer's disease brain points to dysregulation of mitochondrial aspartate metabolism. J Proteome Res2016; 15: 608–618.
36.
SodaTBrunettiVBerra-RomaniR, et al.The emerging role of N-Methyl-D-Aspartate (NMDA) receptors in the cardiovascular system: physiological implications, pathological consequences, and therapeutic perspectives. Int J Mol Sci2023; 24: 3914.
37.
LaubeBHiraiHSturgessM, et al.Molecular determinants of agonist discrimination by NMDA receptor subunits: analysis of the glutamate binding site on the NR2B subunit. Neuron1997; 18: 493–503.
38.
AnsonLCChenPEWyllieDJ, et al.Identification of amino acid residues of the NR2A subunit that control glutamate potency in recombinant NR1/NR2A NMDA receptors. J Neurosci1998; 18: 581–589.
39.
GaravitoMFNarváez-OrtizHYZimmermannBH. Pyrimidine metabolism: dynamic and versatile pathways in pathogens and cellular development. J Genet Genomics2015; 42: 195–205.
40.
PesiniAIglesiasEBayona-BafaluyMP, et al.Brain pyrimidine nucleotide synthesis and Alzheimer disease. Aging2019; 11: 8433–8462.
41.
PetersKHermanSKhoonsariPE, et al.Metabolic drift in the aging nervous system is reflected in human cerebrospinal fluid. Sci Rep2021; 11: 18822.
42.
IvanisevicJStauchKLPetrascheckM, et al.Metabolic drift in the aging brain. Aging (Albany NY)2016; 8: 1000–1020.
43.
WanQLShiXLiuJ, et al.Metabolomic signature associated with reproduction-regulated aging in caenorhabditis elegans. Aging (Albany NY)2017; 9: 447–474.
44.
VaidyanathanK. Molecular diagnosis of urea cycle disorders: current global scenario. Indian J Biochem Biophys2013; 50: 357–362.
45.
ChoiMHKimKRKimIS, et al.Increased hair polyamine levels in patients with Alzheimer's disease. Ann Neurol2001; 50: 128.
46.
BhallaMLeeCJ. Long-term inhibition of ODC1 in APP/PS1 mice rescues amyloid pathology and switches astrocytes from a reactive to active state. Mol Brain2024; 17: 3.
47.
GrahamSFChevallierOPElliottCT, et al.Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease. PloS One2015; 10: e0119452.
48.
FleszarMGWiśniewskiJZbochM, et al.Targeted metabolomic analysis of nitric oxide/L-arginine pathway metabolites in dementia: association with pathology, severity, and structural brain changes. Sci Rep2019; 9: 13764.
49.
VirarkarMAlappatLBradfordPG, et al.L-arginine and nitric oxide in CNS function and neurodegenerative diseases. Crit Rev Food Sci Nutr2013; 53: 1157–1167.
50.
HeJHouTWangQ, et al.L-arginine metabolism ameliorates age-related cognitive impairment by Amuc_1100-mediated gut homeostasis maintaining. Aging Cell2024; 23: e14081.
51.
PervinMUnnoKKonishiT, et al.L-Arginine exerts excellent anti-stress effects on stress-induced shortened lifespan, cognitive decline and depression. Int J Mol Sci2021; 22: 508.
52.
HeJSpanoliosEFroehlichCE, et al.Recent advances in the development and characterization of electrochemical and electrical biosensors for small molecule neurotransmitters. ACS Sens2023; 8: 1391–1403.
53.
AllertonTDProctorDNStephensJM, et al.l-Citrulline supplementation: impact on cardiometabolic health. Nutrients2018; 10: 921.
YaJWhitbyABayraktutanU. Metabolites and metabolic functional changes-potential markers for endothelial cell senescence. Biomolecules2024; 14: 1476.
56.
LongNAGollaUSharmaA, et al.Acute myeloid leukemia stem cells: origin, characteristics, and clinical implications. Stem Cell Rev Rep2022; 18: 1211–1226.
57.
DelwingDChiaraniFDelwingD, et al.Proline reduces acetylcholinesterase activity in cerebral cortex of rats. Metab Brain Dis2003; 18: 79–86.
58.
DelwingDDelwingDChiaraniF, et al.Proline reduces brain cytochrome c oxidase: prevention by antioxidants. Int J Dev Neurosci2007; 25: 17–22.
59.
AnLShenYChoppM, et al.Deficiency of endothelial nitric oxide synthase (eNOS) exacerbates brain damage and cognitive deficit in a mouse model of vascular dementia. Aging Dis2021; 12: 732–746.
KobayashiK. Role of catecholamine signaling in brain and nervous system functions: new insights from mouse molecular genetic study. J Investig Dermatol Symp Proc2001; 6: 115–121.
63.
HenjumKWatneLOGodangK, et al.Cerebrospinal fluid catecholamines in Alzheimer's disease patients with and without biological disease. Transl Psychiatry2022; 12: 151.
64.
HongXYLiSLiT, et al.Differential involvement of central and peripheral catecholamines between Alzheimer's disease and vascular dementia. Heliyon2024; 10: e38843.
65.
AkhterFPersaudAZaokariY, et al.Vascular dementia and underlying sex differences. Front Aging Neurosci2021; 13: 720715.
66.
LicherSDarweeshSKLWoltersFJ, et al.Lifetime risk of common neurological diseases in the elderly population. J Neurol Neurosurg Psychiatry2019; 90: 148–156.
67.
KimMYKimKHongCH, et al.Sex differences in cardiovascular risk factors for dementia. Biomol Ther (Seoul)2018; 26: 521–532.
68.
NicolettiABaschiRCiceroCE, et al.Sex and gender differences in Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis: a narrative review. Mech Ageing Dev2023; 212: 111821.
69.
ExaltoLGBoomsmaJMFBabapour MofradR, et al.Sex differences in memory clinic patients with possible vascular cognitive impairment. Alzheimers Dement (Amst)2020; 12: e12090.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
